News Issued: May 13, 2024 (4:02pm EDT) To view this online and get more information about Novavax Investor Relations visit: NOVAVAX TO PARTICIPATE IN BOFA SECURITIES 2024 HEALTH CARE CONFERENCE GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 15, 2024 Time: 3:00 – 3:30 p.m. Pacific Daylight Time (PDT) Location: Encore Hotel in Las Vegas, NV Moderator: Alec Stranahan, PhD, Equity Research – U.S. Biopharma Novavax participant: John C. Jacobs, President and Chief Executive Officer Conference Event: Investor Meetings Date: Wednesday, May 15, 2024 Recordings A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference. About Novavax Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Contacts: Investors Erika Schultz 240-268-2022 [email protected] Media Giovanna Chandler 202-709-5563 [email protected] Novavax Logo (PRNewsfoto/Novavax) SOURCE Novavax, Inc.